These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24773076)

  • 1. Mycobacterium kansasii cutaneous infection in a patient with sarcoidosis treated with anti-TNF agents.
    Spiliopoulou I; Foka A; Bounas A; Marangos MN
    Acta Clin Belg; 2014 Jun; 69(3):229-31. PubMed ID: 24773076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
    Field S; Regan AO; Sheahan K; Collins P
    Clin Exp Dermatol; 2010 Oct; 35(7):795-6. PubMed ID: 20831604
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous Mycobacterium marinum infection mimicking felon in a patient with psoriatic arthritis treated with infliximab.
    Demitsu T; Yamada T; Umemoto N; Narita T; Kakurai M; Yoneda K
    J Dermatol; 2012 Nov; 39(11):970-1. PubMed ID: 22413775
    [No Abstract]   [Full Text] [Related]  

  • 4. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α].
    Díaz Cuevas Z; Rodríguez-Lozano B; Campos Gutierrez S; Lecuona Fernández M
    Med Clin (Barc); 2014 Feb; 142(4):183-4. PubMed ID: 23877097
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
    Baughman RP; Iannuzzi M
    BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti-tumor necrosis factor-alfa agents.
    Caron J; Michot C; Fabre S; Godreuil S; Guillot B; Dereure O
    J Am Acad Dermatol; 2011 Nov; 65(5):1060-2. PubMed ID: 22000874
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cutaneous infection due to Mycobacterium chelonae during anti-TNF therapy].
    Adenis-Lamarre E; Kostrzewa E; Texier-Maugein J; Doutre MS
    Ann Dermatol Venereol; 2009 Nov; 136(11):811-4. PubMed ID: 19917435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous infection with Mycobacterium kansasii in a patient with myelodysplastic syndrome and Sweet syndrome.
    Sprague J; Leibowitz M; Chiu MW
    Cutis; 2015 Jul; 96(1):E10-2. PubMed ID: 26244358
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous infection due to Mycobacterium kansasii.
    Razavi B; Cleveland MG
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):173-5. PubMed ID: 11109017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Mycobacterium abscessus infection following hair transplant.
    Eustace K; Jolliffe V; Sahota A; Gholam K
    Clin Exp Dermatol; 2016 Oct; 41(7):768-70. PubMed ID: 27663154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Common variable immunodeficiency and sarcoidosis: what is the link?].
    Agostini C; Semenzato G
    Ann Ital Med Int; 2002; 17(2):77-80. PubMed ID: 12150049
    [No Abstract]   [Full Text] [Related]  

  • 12. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.
    Baughman RP; Lower EE; Bradley DA; Raymond LA; Kaufman A
    Chest; 2005 Aug; 128(2):1062-47. PubMed ID: 16100213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intractable Facial Lesion.
    Trout SSK; O'Brien BE; Steele RW
    Clin Pediatr (Phila); 2018 Dec; 57(14):1707-1710. PubMed ID: 30221991
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Mycobacterium kansasii infection in a patient with AIDS post initiation of antiretroviral therapy.
    Mitha M; Naicker P; Taljaard J
    J Infect Dev Ctries; 2011 Jul; 5(7):553-5. PubMed ID: 21795826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.
    Hoffman GS; Merkel PA; Brasington RD; Lenschow DJ; Liang P
    Arthritis Rheum; 2004 Jul; 50(7):2296-304. PubMed ID: 15248230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
    Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
    J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium kansasii Infection in a Patient Receiving Biologic Therapy-Not All Reactive Interferon Gamma Release Assays Are Tuberculosis.
    Saleem N; Saba R; Maddika S; Weinstein M
    Am J Med Sci; 2017 Apr; 353(4):394-397. PubMed ID: 28317629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
    Sweiss NJ; Curran J; Baughman RP
    Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.
    Yim K; Nazeer SH; Kiska D; Rose FB; Brown D; Cynamon MH
    Scand J Infect Dis; 2004; 36(2):150-4. PubMed ID: 15061673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.